Grants4Apps Accelerator and new Dealmaker now open for submissions

The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.

Grants4Apps Accelerator Berlin 2017

Startups receive € 50,000 each as well as office space in the Bayer Pharmaceuticals Headquarters. Additionally, C-level mentors will support in refining business models, validating technologies and more.

The Grants4Apps team is looking for startups with innovative healthcare solutions. The team is open for any healthcare topics and will give special attention to Bayer-relevant focus areas. This year Grants4Apps is focusing on digital health solutions in the areas of Nephrology (e.g., Chronic Kidney Disease), Women's Health (e.g., Endometriosis), Pulmonology (e.g., Pulmonary Hypertension), Cardiology (e.g., Atrial Fibrillation), Hematology, Oncology, Radiology, Infectious Diseases and Ophthalmology (e.g., Diabetic Retinopathy).

Grants4Apps is also calling for collaboration projects using software or hardware to be applied in clinical trials and medical IT using state-of-the art-technologies such as artificial intelligence, machine learning, deep learning, sophisticated algorithms, bioinformatics, genomics analysis, novel approaches for Electronic Health Records (EHR) etc. - in short: highly innovative technologies with a taste for excellent simplicity and unbeatable user experience focus.

Submission deadline: 31 May 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/accelerator-berlin-2017/

Dealmaker Berlin 2017

Don't need acceleration? Want to gain Bayer as a potential customer? Then this is for you! Mature startups can apply to solve specific 'Bayer challenges'. The top startup matches will have the opportunity to come to Berlin in September (travelling costs will be covered by Bayer) and to sign a potential project deal, please find the challenge you can solve.

If there is a match, you will be inviteed to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Applicants are asked to address one or multiple challenges. However, the Dealmaker is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Human clinical trial reveals verapamil as an effec…

Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

New small molecules pave the way for treating auto…

The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to elimina...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...

Amgen and MBC Biolabs announce winners of the Amge…

Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company recei...

FDA warns of imposters sending consumers fake warn…

The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or ove...